Becton Dickinson Shares Drop 1.05% as FDA Application Sparks Sell-off Trading Volume Surges to 199th Ranks 148th by August 1

Becton Dickinson (BDX) closed August 1, 2025, down 1.05% with $820 million in trading volume, ranking 148th in market activity. The decline followed a sharp sell-off on July 31 amid a $670 million volume spike (199th in market activity) after the company submitted an FDA application for an at-home HPV testing kit. The automated BD COR™ System-enabled test aims to detect more high-risk HPV strains than existing alternatives, addressing unmet demand as 72% of U.S. women delay gynecology visits due to convenience concerns, per a Harris Poll survey.

Technical indicators on the 15-minute chart showed an RSI below oversold levels and a KDJ Golden Cross at 11:00 AM August 1, 2025, signaling potential short-term reversal. While fundamentals remain stable, the rapid price drop suggests temporary momentum shifts driven by regulatory filing-related volatility. The FDA filing aligns with BD’s strategy to expand accessible diagnostics, integrating the Onclarity™ Assay into clinical guidelines despite uncertainties around approval timelines and adoption rates.

A backtested strategy purchasing top 500 high-volume stocks and holding for one day generated 166.71% returns from 2022 to July 30, 2025, outperforming the benchmark by 137.53%. This highlights liquidity-driven momentum opportunities, particularly for stocks like BD with volume spikes linked to product announcements. The approach underscores short-term volatility as a catalyst for returns in concentrated liquidity environments.